Incorporating Prostate Health Index Density, MRI, and Prior Negative Biopsy Status to Improve the Detection of Clinically Significant Prostate Cancer

ConclusionsIn this contemporary cohort of men undergoing prostate biopsy for the diagnosis of PCa, PHID outperformed PHI and other PSA‐derivatives for the diagnosis of clinically‐significant cancer. Incorporating age, PNB status, and PIRADS score led to even further gains in the diagnostic performance of PHID. Furthermore, PIRADS score was found to be complementary to PHID. Using 0.44 as a cutoff for PHID, 35.3% of unnecessary biopsies could have been avoided at the cost of missing 7.7% of clinically‐significant cancers. Despite these encouraging results, prospective validation is needed.This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fbju.14098

Source: BJU International - December 12, 2017 Category: Urology & Nephrology Authors: Sasha C. Druskin, Jeffrey J. Tosoian, Allen Young, Sarah Collica, Arnav Srivastava, Kamyar Ghabili, Katarzyna J. Macura, Ballentine H Carter, Alan W. Partin, Lori J. Sokoll, Ashley E. Ross, Christian P. Pavlovich Tags: Original Article Source Type: research